In today’s session GW Pharmaceuticals PLC- ADR (GWPH) registered an unusually high (1,891) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious GWPH increase. With 1,891 contracts traded and 4194 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: GWPH161118C00125000 closed last at: $2.6 or 8.8% down. About 106,467 shares traded hands. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has risen 65.52% since March 30, 2016 and is uptrending. It has outperformed by 62.51% the S&P500.
Analysts await GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to report earnings on December, 5. They expect $-1.59 EPS, down 87.06% or $0.74 from last year’s $-0.85 per share. After $-0.73 actual EPS reported by GW Pharmaceuticals PLC- ADR for the previous quarter, Wall Street now forecasts 117.81% negative EPS growth.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Ratings Coverage
Out of 8 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. GW Pharmaceuticals has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Roth Capital maintained the stock with “Buy” rating in Monday, March 14 report. As per Monday, September 26, the company rating was maintained by Cantor Fitzgerald. Roth Capital initiated the shares of GWPH in a report on Monday, November 30 with “Buy” rating. On Monday, June 27 the stock rating was initiated by Janney Capital with “Sell”. The company was initiated on Monday, November 30 by TH Capital. The firm earned “Buy” rating on Friday, June 3 by Cantor Fitzgerald. The stock of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has “Buy” rating given on Friday, October 7 by Goldman Sachs. Numis Securities upgraded GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) on Friday, August 26 to “Hold” rating. Morgan Stanley initiated it with “Overweight” rating and $150 target price in Thursday, August 13 report.
According to Zacks Investment Research, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.”
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The company has a market cap of $2.93 billion. The Firm develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. It currently has negative earnings. The Firm operates through three divisions: Commercial, Sativex Research and Development , and Pipeline Research and Development.
More important recent GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on April 27, 2013, also Marketwatch.com published article titled: “GW Pharmaceuticals PLC ADR”, Investorplace.com published: “GW Pharmaceuticals PLC- ADR Is a First-Rate Marijuana Stock (GWPH)” on September 26, 2016. More interesting news about GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) was released by: Investorplace.com and their article: “GW Pharmaceuticals PLC- ADR (GWPH) Boards the Buyout Rumor Mill” with publication date: September 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.